Scotland-founded · UK Plant Genetics company

Genetics, characterised.

Developing differentiated plant cultivars through evidence-led selection, structured protection and integration with licensed operators.

Explore our model ↘

MEET AURELIS®

Cultivar-development pathway: selection, evidence, protection and integration

Foundation

Scotland

Model

Partner-led

Market

Regulated

OUR APPROACH

Built carefully.

Designed to integrate.

Caledonia Pharms develops cultivar assets for regulated supply chains. The model joins plant selection with the evidence, protection and licensed infrastructure required around it.

DISCOVER

Identify differentiated expression

Phenotype and chemotype screening.

DOCUMENT

Build a defensible record

Independent analysis, provenance and clonal continuity.

INTEGRATE

Prepare for licensed deployment

Protection and partner-led pathways for regulated supply chains.

Selection with a reason.

Phenotype selection

Chemotype differentiation

Clonal preservation

Focus on differentiated expression rather than portfolio volume.

A differentiated cultivar, developed as an asset.

AURELIS® (CP-01) is a differentiated, clone-only cultivar supported by a continuity record dating to its original selection in 2021. Its emerging dossier combines independent chemistry, retained provenance and plant-protection preparation.

ND — Replicated myrcene non-detect

2021 — Selection and continuity record

® Registered

UK trade mark

Request a private briefing ↗

For licensed operators, research partners and professional advisers.

Caledonia Pharms Ltd

Evidence-led plant genetics

5 South Charlotte Street · Edinburgh EH2 4AN · United Kingdom

Caledonia Pharms develops genetics and partnership frameworks for regulated markets. It does not supply consumer products.